These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 17537600)

  • 1. A material science perspective of pharmaceutical solids.
    Cui Y
    Int J Pharm; 2007 Jul; 339(1-2):3-18. PubMed ID: 17537600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perspectives in the use of spectroscopy to characterise pharmaceutical solids.
    Aaltonen J; Gordon KC; Strachan CJ; Rades T
    Int J Pharm; 2008 Dec; 364(2):159-69. PubMed ID: 18555625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thermotropic liquid crystalline drugs.
    Bunjes H; Rades T
    J Pharm Pharmacol; 2005 Jul; 57(7):807-16. PubMed ID: 15969938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase transformation considerations during process development and manufacture of solid oral dosage forms.
    Zhang GG; Law D; Schmitt EA; Qiu Y
    Adv Drug Deliv Rev; 2004 Feb; 56(3):371-90. PubMed ID: 14962587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. General principles of pharmaceutical solid polymorphism: a supramolecular perspective.
    Rodríguez-Spong B; Price CP; Jayasankar A; Matzger AJ; Rodríguez-Hornedo N
    Adv Drug Deliv Rev; 2004 Feb; 56(3):241-74. PubMed ID: 14962581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and mesomorphic properties of rigid-core ionic liquid crystals.
    Kouwer PH; Swager TM
    J Am Chem Soc; 2007 Nov; 129(45):14042-52. PubMed ID: 17949091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Solid form screening--a review.
    Aaltonen J; Allesø M; Mirza S; Koradia V; Gordon KC; Rantanen J
    Eur J Pharm Biopharm; 2009 Jan; 71(1):23-37. PubMed ID: 18715549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crystal polymorphism in chemical process development.
    Lee AY; Erdemir D; Myerson AS
    Annu Rev Chem Biomol Eng; 2011; 2():259-80. PubMed ID: 22432619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Solid state amorphization of pharmaceuticals.
    Willart JF; Descamps M
    Mol Pharm; 2008; 5(6):905-20. PubMed ID: 18954076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Solubility of molecular crystals: polymorphism in the light of solubility theory.
    Bennema P; van Eupen J; van der Wolf BM; Los JH; Meekes H
    Int J Pharm; 2008 Mar; 351(1-2):74-91. PubMed ID: 17980982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals represent a new path to improved medicines?
    Almarsson O; Zaworotko MJ
    Chem Commun (Camb); 2004 Sep; (17):1889-96. PubMed ID: 15340589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of cocrystals in pharmaceutical science.
    Shan N; Zaworotko MJ
    Drug Discov Today; 2008 May; 13(9-10):440-6. PubMed ID: 18468562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of solid-state transformations of pharmaceutical compounds using vibrational spectroscopy.
    Heinz A; Strachan CJ; Gordon KC; Rades T
    J Pharm Pharmacol; 2009 Aug; 61(8):971-88. PubMed ID: 19703341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selecting and controlling API crystal form for pharmaceutical development--strategies and processes.
    Yin SX; Grosso JA
    Curr Opin Drug Discov Devel; 2008 Nov; 11(6):771-7. PubMed ID: 18946842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crystalline mesophases: Structure, mobility, and pharmaceutical properties.
    Shalaev E; Wu K; Shamblin S; Krzyzaniak JF; Descamps M
    Adv Drug Deliv Rev; 2016 May; 100():194-211. PubMed ID: 27067607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmaceutical liquid crystals: the relevance of partially ordered systems.
    Stevenson CL; Bennett DB; Lechuga-Ballesteros D
    J Pharm Sci; 2005 Sep; 94(9):1861-80. PubMed ID: 16052511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nucleation of crystals from solution: classical and two-step models.
    Erdemir D; Lee AY; Myerson AS
    Acc Chem Res; 2009 May; 42(5):621-9. PubMed ID: 19402623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates.
    Blagden N; de Matas M; Gavan PT; York P
    Adv Drug Deliv Rev; 2007 Jul; 59(7):617-30. PubMed ID: 17597252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Supramolecular control of reactivity in the solid state: from templates to ladderanes to metal-organic frameworks.
    MacGillivray LR; Papaefstathiou GS; Friscić T; Hamilton TD; Bucar DK; Chu Q; Varshney DB; Georgiev IG
    Acc Chem Res; 2008 Feb; 41(2):280-91. PubMed ID: 18281948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expanding the scope of crystal form evaluation in pharmaceutical science.
    Peterson ML; Hickey MB; Zaworotko MJ; Almarsson O
    J Pharm Pharm Sci; 2006; 9(3):317-26. PubMed ID: 17207415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.